Health-Holland

2014 2015 2016 2017 uniQure $ 92 mln Sapiens $ 200 mln Prosensa $ 840 mln uniQure $ 571 mln Galapagos $ 318 mln AM-Pharma $ 600 mln Dezima Pharma $ 1.55 bln Acerta Pharma $ 7 bln Galapagos $ 2.1 bln Merus $ 200 mln WIL Research $ 585 mln IPO, licence deal or private venture Merger / acquisition Recent mergers and deals In recent years, several Dutch biopharmaceutical companies have attracted investments from larger pharmaceutical companies, occasionally resulting in the acquisition of the Dutch company. Furthermore, several companies have launched successful IPOs (Initial Public Offering) on Wall Street. Largest IPOs and mergers/acquisitions: IPOs Galapagos: $317 mln uniQure: $91.8 mln Merus: $42.5 mln Mergers/acquisitions Acerta Pharma: max $7 bln Dezima Pharma: $1.55 bln WIL Research: $585 mln Significant Partnerships (ex. royalties) Galapagos/Gilead: $725 mln Galapagos/Abbvie: $600 mln uniQure/BMS: $245 mln ProQr $ 112 mln Mergers and IPOs 23